DGAP-News: Vivoryon Therapeutics AG
/ Key word(s): Contract
Vivoryon Therapeutics and Nordic Bioscience Enter Research and Development Collaboration
HALLE (SAALE), Germany and Herlev, Denmark, 14 January 2020 - Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) and Nordic Bioscience, announced today an agreement to collaborate for the clinical development of PQ912 for Alzheimer's Disease (AD). In addition to taking on the role as CRO (Clinical Research Organization) for Vivoryon Therapeutics' Phase 2b SAPHIR 2 trial, Nordic Bioscience and Vivoryon will enter into a collaboration to benefit from Nordic Bioscience's world leading expertise in the development of blood-based biomarkers for the identification of specific patients that may benefit most from treatment with PQ912, the Company's Phase 2 clinical-stage candidate in AD.
Current methods used to diagnose AD remain invasive and relatively complex. Therefore, there is a need to develop and establish reliable, less invasive and efficient biomarkers and technologies in clinical practice. To address this, Nordic Bioscience has been pioneering the development of blood-based biomarkers for decades and is therefore the ideal partner for identifying molecular fingerprints in blood of patients. This supports Vivoryon's therapeutic approach of targeting neurotoxic pGlu-Abeta by inhibiting its producing enzyme Glutaminyl Cyclase.
For the biomarker activities, blood samples of patients in the European SAPHIR 2 Phase 2b trial will be collected and analyzed by a mutual team of scientists from Nordic Bioscience and Vivoryon Therapeutics with the goal to identify correlations with clinical responses.
"We believe our collaboration with Nordic Bioscience has the potential to bring tremendous benefit to patients suffering from this complex and devastating disease. The ability to select patients who have a greater chance of responding to PQ912 could transfer an already proven principle of precision medicine into Alzheimer's Disease. We look forward to the start of our Phase 2b clinical trial in the first quarter of 2020." commented Dr. Ulrich Dauer, CEO of Vivoryon Therapeutics AG.
"Vivoryon's approach to treating Alzheimer's disease provides multiple options to identify predictive response markers in blood. As such, we are excited about the potential of this partnership." said Claus Christiansen, Chairman of Nordic Bioscience.
About Vivoryon Therapeutics AG
Forward Looking Statements
|Vivoryon Therapeutics AG
|+49 (0)345 555 9900
|+49 (0)345 555 9901
|Regulated Unofficial Market in Berlin, Frankfurt, Munich, Stuttgart; Amsterdam
|EQS News ID:
|End of News
|DGAP News Service